Related Experiment Video
Updated: Aug 25, 2026

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
Published on: September 8, 2021
Decreased 5-HT1A receptor binding in amygdala of schizophrenia
Fumihiko Yasuno1, Tetsuya Suhara, Tetsuya Ichimiya
1Department of Psychiatry (YO), Nippon Medical School, Tokyo, Japan.
Background:
On the basis of postmortem data and the pharmacological action of atypical antipsychotics, serotonin-1A receptors are of interest in the study of the pathophysiology of schizophrenia. To investigate serotonin-1A receptors in schizophrenia and their relation to symptoms, we measured the availability of serotonin-1A receptors in patients with schizophrenia using positron emission tomography with [carbonyl-(11)C]WAY-100635.
Methods:
Serotonin-1A receptor binding of 11 patients with schizophrenia (8 drug-naive and 3 drug-free) was compared with that of 22 age-matched and gender-matched healthy control subjects. Symptoms were assessed using the Positive and Negative Syndrome Scale. Serotonin-1A receptor binding in selected regions of interest was quantified by binding potential obtained by the reference tissue method.
Results:
The regional binding potential value was lower in the amygdala by about 19% in patients with schizophrenia than in normal controls. A significant negative correlation was observed between binding potential in the amygdala and the negative and depression/anxiety symptom scores on the five-symptom subscale of the Positive and Negative Syndrome Scale.
Conclusions:
Decreased serotonin-1A receptor binding in the amygdala may underlie the affective components included in the symptoms of negative and depression/anxiety in schizophrenia.
Related Concept Videos
G-protein Coupled Receptors
Role of Amygdala in Memory
One of the...
Drugs Affecting Neurotransmitter Release or Uptake
Antipsychotic Drugs: Typical and Atypical Agents
Biological Causes of Schizophrenia
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin studies.
Antidepressant Drugs: MAOIs and Other Agents
